JP2009511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511632A5
JP2009511632A5 JP2008536724A JP2008536724A JP2009511632A5 JP 2009511632 A5 JP2009511632 A5 JP 2009511632A5 JP 2008536724 A JP2008536724 A JP 2008536724A JP 2008536724 A JP2008536724 A JP 2008536724A JP 2009511632 A5 JP2009511632 A5 JP 2009511632A5
Authority
JP
Japan
Prior art keywords
composition
retinal
disease
kit
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008536724A
Other languages
English (en)
Japanese (ja)
Other versions
JP5745208B2 (ja
JP2009511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/040429 external-priority patent/WO2007047607A2/en
Publication of JP2009511632A publication Critical patent/JP2009511632A/ja
Publication of JP2009511632A5 publication Critical patent/JP2009511632A5/ja
Application granted granted Critical
Publication of JP5745208B2 publication Critical patent/JP5745208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008536724A 2005-10-18 2006-10-17 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 Active JP5745208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72820905P 2005-10-18 2005-10-18
US60/728,209 2005-10-18
PCT/US2006/040429 WO2007047607A2 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013213746A Division JP2014028855A (ja) 2005-10-18 2013-10-11 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Publications (3)

Publication Number Publication Date
JP2009511632A JP2009511632A (ja) 2009-03-19
JP2009511632A5 true JP2009511632A5 (enExample) 2009-11-12
JP5745208B2 JP5745208B2 (ja) 2015-07-08

Family

ID=37872252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008536724A Active JP5745208B2 (ja) 2005-10-18 2006-10-17 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
JP2013213746A Withdrawn JP2014028855A (ja) 2005-10-18 2013-10-11 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013213746A Withdrawn JP2014028855A (ja) 2005-10-18 2013-10-11 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Country Status (11)

Country Link
US (5) US8062657B2 (enExample)
EP (1) EP1937210B1 (enExample)
JP (2) JP5745208B2 (enExample)
KR (1) KR101430760B1 (enExample)
CN (1) CN101394834A (enExample)
AU (1) AU2006304416B2 (enExample)
BR (1) BRPI0613401B8 (enExample)
CA (1) CA2602577C (enExample)
MX (2) MX2007012061A (enExample)
NZ (1) NZ562032A (enExample)
WO (1) WO2007047607A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CA2602577C (en) * 2005-10-18 2015-03-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
PL2214646T3 (pl) 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3412260B1 (en) 2009-05-18 2020-08-26 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2515864A4 (en) * 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
US10501779B2 (en) * 2011-05-12 2019-12-10 President And Fellows Of Harvard College Oligonucleotide trapping
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
DK3517541T3 (da) 2012-05-08 2020-09-07 Nicox Ophthalmics Inc Polymorf form af fluticasonpropionat
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10369124B2 (en) 2014-04-30 2019-08-06 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN106573070A (zh) 2014-08-13 2017-04-19 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017062407A1 (en) * 2015-10-07 2017-04-13 Genentech, Inc. Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
WO2019043179A1 (en) * 2017-09-01 2019-03-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) COMPOSITIONS FOR THE TREATMENT OF MACULAR EDEMA
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
AU604236B2 (en) 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
ES2078175B1 (es) 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
DE69734290T2 (de) 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
AU738338B2 (en) * 1997-08-11 2001-09-13 Allergan, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) * 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US20030185892A1 (en) 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
DE60231742D1 (de) 2001-12-12 2009-05-07 Rhodia Chimie Sa Formulierung enthaltend eine anionische verbindung, ein polyionisches polymer und ein copolymer
US6873524B2 (en) * 2002-08-15 2005-03-29 Audavi Corporation Data storage device
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2004073607A2 (en) 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AU2005209201B2 (en) * 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
CA2602577C (en) * 2005-10-18 2015-03-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
JP2007309763A (ja) 2006-05-18 2007-11-29 Sumitomo Electric Ind Ltd 電線の表面欠陥検出装置

Similar Documents

Publication Publication Date Title
JP2009511632A5 (enExample)
RU2521338C9 (ru) Способ лечения атрофической возрастной макулярной дегенерации
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
ES2851748T3 (es) Procedimientos para la fabricación de implantes lipídicos cíclicos para uso intraocular
US10959954B2 (en) Dexamethasone prodrug compositions and uses thereof
JP2008505978A (ja) 眼病用組成物および眼病治療法
JP2007535552A5 (enExample)
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
CA3096838A1 (en) Methods and compositions for sustained release microparticles for ocular drug delivery
JP2018503736A (ja) 眼内圧を抑える抗緑内障剤の持続放出のための組成物
US12473326B2 (en) Crystalline forms of dexamethasone dimers and uses thereof
CA2598095A1 (en) Method of relieving or avoiding side effect of steroid
JP2013501794A (ja) 目の疾患を治療するためのイソチオゾール
WO2021237096A1 (en) Durable implants and microparticles for long-term ocular therapy
US20110257186A1 (en) Compositions and methods for treating visual disorders
US20250367130A1 (en) Thermoresponsive hydrogel containing metal-organic framework particles for noninvasive ocular drug delivery